Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 26, 2015 10:37am

115 Views

Post# 23563911

RE: BLOG ADDITION

The subject of this blog invovles a new name I don't recall seeing before:

Dr. Jorge Plutzky, associate professor at Harvard Medical School and director of the Vascular Disease Prevention Program

I wonder if his research is entirely independent from the work Resverlogix has been doing or whether there has been some collarboration. It seems that the subject matter is closely related....

This seems a sign that the technology behind RVX-208 is getting wider attention and perhaps acceptance within the medical profession.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns